Zynex is a medical distribution business based in the US. Zynex shares (ZYXI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.44 – an increase of 11.93% over the previous week. Zynex employs 1,000 staff and has a trailing 12-month revenue of around $192.4 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.44 |
|---|---|
| 52-week range | $1.93 - $12.19 |
| 50-day moving average | $4.73 |
| 200-day moving average | $7.39 |
| Wall St. target price | $10.00 |
| PE ratio | 24.2222 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.09 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.26 from 2025-04-22
| 1 week (2025-04-17) | 3.67% |
|---|---|
| 1 month (2025-03-25) | -11.02% |
| 3 months (2025-01-24) | -72.97% |
| 6 months (2024-10-25) | -75.22% |
| 1 year (2024-04-25) | -79.34% |
|---|---|
| 2 years (2023-04-24) | -80.81% |
| 3 years (2022-04-22) | 7.03 |
| 5 years (2020-04-24) | 13.4644 |
Valuing Zynex stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zynex's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Zynex's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Zynex shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Zynex's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.8 million.
The EBITDA is a measure of a Zynex's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $192.4 million |
|---|---|
| Gross profit TTM | $153.3 million |
| Return on assets TTM | 2.89% |
| Return on equity TTM | 7.32% |
| Profit margin | 1.56% |
| Book value | $1.12 |
| Market Capitalization | $65.9 million |
TTM: trailing 12 months
We're not expecting Zynex to pay a dividend over the next 12 months.
Zynex's shares were split on a 11:10 basis on 4 January 2022 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 11 shares. This wouldn't directly have changed the overall worth of your Zynex shares – just the quantity. However, indirectly, the new 9.1% lower share price could have impacted the market appetite for Zynex shares which in turn could have impacted Zynex's share price.
Over the last 12 months, Zynex's shares have ranged in value from as little as $1.93 up to $12.1896. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zynex's is 1.101. This would suggest that Zynex's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Zynex, Inc. , together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.